Targeted prevention of diabetes
Every year, about 560,000 people in Germany are newly diagnosed with diabetes. This figure clearly shows the importance of targeted prevention. At the symposium "Precise Prevention Strategies", led by DZD scientist Professor Andreas Fritsche, researchers will provide information on the current state of knowledge on diabetes prevention for type 2 diabetes, type 1 diabetes and gestational diabetes. (November 6th from 2:25 p.m.)

Lectures (in German)

• Prevention of type 2 diabetes and its secondary diseases: significance of the high-risk subgroups, A. Fritsche (Tübingen)
• Prevention of type 1 diabetes, B. Marcus (München)
• Prevention of gestational diabetes, L. Fritsche (Tübingen)

Involving patients
Involving the patient can be a building block for successful treatment. In the symposium "Participatory decision-making and therapeutic adherence in diabetes" led by Professor Monika Kellerer and DZD scientist Professor Bernd Kulzer will present what participatory decision-making can look like. At the symposium, DZD Managing Director Dr. Astrid Glaser and Ulrike Koller will present the new national diabetes information portal www.diabinfo.de. The portal offers up-to-date, neutral and scientifically verified information on all forms of diabetes mellitus and the prevention of diabetes. (November 6th from 3:45 p.m.)

Lectures (in German)

• National diabetes information portal – diabinfo: A building block for participatory decision-making? A. Glaser (Neuherberg)
• Therapy adherence in diabetes: State of the art, B. Kulzer (Bad Mergentheim)
• Participatory decision-making and therapy adherence in the new NVL type 2 diabetes, F. Petrak (Wiesbaden)
• Absolute Algorithm? Criticism of a rationalization of the doctor-patient relationship, B. Kalvelage (Hamburg)

Liver and diabetes
Non-alcoholic fatty liver disease (NAFLD) plays an important role in obesity and the development of type 2 diabetes mellitus. In the symposium "Diabetes and Liver/NASH" led by Prof. Dr. Thomas Forst and Prof. Dr. Nobert Stefan (DZD) the clinical significance of fatty liver, especially in connection with type 2 diabetes and its cardiovascular complications, will be discussed. (November 7th from 9:00 a.m.)

Lectures (in German)

• Cause and clinical significance of NASH in patients with diabetes mellitus, M. Roden (Düsseldorf)
• Importance of lifestyle and nutrition in NAFLD and NASH, N. Stefan (Tübingen)
• Diabetes mellitus and NASH – Therapeutic options and outlook for new therapy approaches, J. Schattenberg (Mainz)

Diabetes subtypes
Not all diabetes is the same. Current research shows that there are different subgroups of the metabolic disease. The new classification can help treat diabetes more precisely and avoid secondary diseases. How this looks in practice is highlighted by the symposium “Practical Significance of New Diabetes Classifications” under the direction of Professor Roden and Priv.-Doz. Julia Szendrödi, MD (both DZD) from different perspectives. But there are not only subtypes in diabetes. A distinction can already be made between different subgroups in people with impaired blood sugar metabolism who have a preliminary stage of diabetes (prediabetes). Professor Fritsche will present new research results from the DZD.

Lectures (in German)

• A new classification of prediabetes, A. Fritsche (Tübingen)
• New subtypes/cluster and risk for diabetes sequelae, J. Szendrödi (Düsseldorf)
• Perspectives of the new diabetes classification for diabetes therapy, D. Müller-Wieland (Aachen)

DZD researchers are also active as speakers at numerous other symposia. There they will present, among other things, programs for the early detection of type 1 diabetes, the effects of social differences on treatment, diabetes management and lifestyle, a diabetes app and information on psychological support for diabetes in old age using modern technologies.

You can find the complete program here.